Both of DiaCarta’s EUA authorized SARS-CoV-2 molecular diagnostic tests are listed in FDA website as among the top tier out of 117 in terms of sensitivity of the test with Limit of Detection (LoD) 600 NDU/mL or better.
DiaCarta’s qRT-PCR COVID-19 Tests are at the Top Tier of All 117 EUA authorized SARS-CoV-2 Tests in Terms of Sensitivity of the Test
DiaCarta is a leading translational genomics and personalized diagnostics company based in Pleasanton, California with significant business operations in China. DiaCarta provides highly sensitive and advanced technologies that will change the landscape of precision medicine and molecular diagnostics by impacting healthcare treatment plans and the well-being of individuals around the world.
SuperbDNA™ technology uses branched DNA to qualitatively or quantitatively measure the presence of target DNA or RNA. Unlike PCR or RT-PCR, SuperbDNA™ technology does not amplify the DNA or RNA in the samples, rather amplifies the signals for detection. Because the amplified signal is proportional to the levels of the target (DNA or RNA) in the samples, the latter is easy to be quantified with a standard curve. SuperbDNA™ technology has been used in FDA-approved clinical applications, including prognosis and monitoring of patients with viral diseases.
DiaCarta Inc., a precision molecular diagnostics company and leading developer of novel oncology tests using liquid biopsy, today announced the appointment of Jack Kaye, retired Partner with Deloitte LLP, as an independent board member who will serve as the Chairman of the Company’s Audit Committee.
DiaCarta Enters a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) to Develop Cancer Tests based on its Novel XNA Technology
DiaCarta Inc., a precision molecular diagnostics company and leading developer of novel oncology tests using liquid biopsy today announced that the company, under a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI), part of the National Institutes of Health, will collaborate on the evaluation and development of DiaCarta’s proprietary xeno-nucleic acid (XNA) molecular clamping technology. NCI and DiaCarta will collaborate on the following projects: (1) the investigation of low frequency mutation events in cancers and rare diseases using DiaCarta’s proprietary xeno-nucleic acid (XNA) molecular clamping technology, and (2) the development of XNA probes for in situ cancer cell detection. The duration of the CRADA will be 2 years from the effective start date.
linkedinfacebooktwitterCancer deaths due to failure of early detection According to the American Cancer Society researchers, it is estimated that there will be more than 600,000 people die of cancer, and 1.9 million new cancer cases in the US in 2021 alone....
linkedinfacebooktwitterWritten by Chris Wolskiat Clinical Lab Products Read the article on Clinical Lab Products